Skip to main content

Market Overview

Reasons To Stay Bullish On Alnylam In The New Year

Reasons To Stay Bullish On Alnylam In The New Year

At its R&D Day in New York City on December 16, Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) discussed its clinical pipeline of RNAi drugs, including the phase III APOLLO trial of patisiran for transthyretin familial amyloid polyneuropathy (TTR-FAP).

Chardan Capital’s Madhu Kumar maintains a Buy rating on the company, while lowering the price target from $89 to $69.

Bullish Stance

Expressing a bullish stance on Alnylam Pharma ahead of the data from the APOLLO trial in 2017, Kumar mentioned that the “opt-in to co-develop and co-commercialize fitusiran” in partnership with Sanofi SA (ADR) (NYSE: SNY) is a positive for Alnylam Pharma.

At its R&D Day, the company provided further details regarding the recently discontinued revusiran program for TTR familial amyloid cardiomyopathy (TTR-FAC).


However, the analyst believes there are still meaningful uncertainties regarding the future of the company’s TTR-FAC therapeutic strategy.

Alnylam Pharma presented the Phase I and Phase II data for ALN-CC5 in paroxysmal nocturnal hemoglobinuria (PNH) on December 5 at the American Society of Hematology Annual Meeting & Exposition.

Kumar, however, believes the PNH landscape has “fundamentally changed with LDH normalization serving as the new standard for competitiveness.”

The market share estimate for ALN-CC5 has therefore been lowered from peak share of 15.4 percent to 5.4 percent.

At Last Check

Latest Ratings for ALNY

Apr 2021Morgan StanleyMaintainsOverweight
Feb 2021GuggenheimDowngradesBuyNeutral
Feb 2021BarclaysMaintainsOverweight

View More Analyst Ratings for ALNY
View the Latest Analyst Ratings


Related Articles (ALNY + SNY)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech Long Ideas News Health Care Price Target Reiteration Analyst Ratings Best of Benzinga

Latest Ratings

PHXSeaport GlobalInitiates Coverage On
AFCGLake StreetInitiates Coverage On29.0
OSSNoble Capital MarketsUpgrades7.0
NCNOGabelli & Co.Upgrades
HAECJS SecuritiesUpgrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at